期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/ijms22147641
关键词
Bruton's kinase; Btk inhibitors; ibrutinib; drug delivery; cancer treatment
In recent years, Btk inhibitors have emerged as a new target in medicinal chemistry, with reversible compounds being developed to overcome the limitations of irreversible inhibitors. Clinical trials and preclinical investigations have been conducted for malignancies, chronic inflammation conditions, and SARS-CoV-2 infection. Nanoformulations are also being studied to increase the bioavailability of ibrutinib.
In the past few years, Bruton's tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk inhibitors have been launched on the market. In the attempt to overcome irreversible Btk inhibitor limitations, reversible compounds have been developed and are currently under evaluation. In recent years, many Btk inhibitors have been patented and reported in the literature. In this review, we summarized the (ir)reversible Btk inhibitors recently developed and studied clinical trials and preclinical investigations for malignancies, chronic inflammation conditions and SARS-CoV-2 infection, covering advances in the field of medicinal chemistry. Furthermore, the nanoformulations studied to increase ibrutinib bioavailability are reported.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据